Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 01 - 18 tags : Phase 2 save search
ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival
Published: 2022-01-18 (Crawled : 00:00) - biospace.com/
FNCTF | $11.128 -20.84% 580
|
Communications
|
| O: -0.4%
H: 0.0%
C: -0.58%
IBRX | $5.235 2.45% 2.39% 3.8M
|
Manufacturing
|
| O: -1.27%
H: 0.0%
C: 0.0%
phase 2 trial disease media asco cancer pancreatic
Global Coalition for Adaptive Research Announces Key Updates on GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients With Glioblastoma
Published: 2022-01-18 (Crawled : 22:00) - biospace.com/
BHVN | $44.77 -15.66% -1.94% 3.4M
|
Health Technology
|
| O: -1.78%
H: 0.59%
C: -1.67%
phase 2 research trial platform glioblastoma
Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research
Published: 2022-01-18 (Crawled : 22:00) - biospace.com/
CMRX | $0.9129 -4.98% -5.24% 510K
|
Health Technology
|
| O: -1.33%
H: 1.52%
C: -5.07%
onc201 phase 2 research positive endocrine cancer
Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
RFL 4 | $1.82 9.64% -3.85% 72K
|
Finance
|
| O: 0.4%
H: 0.0%
C: -8.42%
cpi-613 613 phase 2 als ongoing trial gemcitabine cancer enroll
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
IMAB | $1.81 0.0% 400K
|
Health Technology
|
| O: -8.6%
H: 5.62%
C: 2.83%
phase 2 solid tumors trial china
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler)
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
SRNE | $0.3073 -20.27% -8.85% 0
|
Health Technology
|
| O: 2.35%
H: 0.0%
C: 0.0%
covid-19 health phase 2 trial covid brazil
Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
EVAX | $4.03 3.6% 3.47% 45K
|
Manufacturing
|
| O: 3.91%
H: 0.0%
C: -6.12%
evx-01 keytruda treatment phase 2 clearance trial biotech iot
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
HOOK | $0.739 -6.04% -6.43% 660K
|
Health Technology
|
| O: 0.0%
H: 2.44%
C: -1.46%
hb-200 fast track designation treatment fda phase 2 fast track trial report cancer enroll designation
Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trial
Published: 2022-01-18 (Crawled : 07:00) - biospace.com/
IONS | $41.56 -0.43% -0.43% 760K
|
Health Technology
|
| O: 3.23%
H: 0.0%
C: 0.0%
huntington phase 2 trial disease huntington’s disease
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.